Pharma

Your Article Summary

See Latest Articles

Cytokinetics, Incorporated Reports Third Quarter 2009 Financial Results
Cytokinetics, 10/29/09

Cytokinetics, Incorporated reported revenues from research and development collaborations of $5.5 million for the third quarter of 2009. The net loss for the third quarter was $8.2 million, or $0.14 per basic and diluted share. This compared to a net loss of $16.3 million, or $0.33 per basic and diluted share, for the same period in 2008. As of September, 2009, cash, cash equivalents and investments, excluding restricted cash and the put option on the company's auction rate securities, totaled $119.2 million.

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

HP to Acquire Networking Firm 3Com
HealthDataManagement, 11/20/09

Protox Reports 2009 Third Quarter Results
Protox Therapeutics , 11/18/09

King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
King Pharmaceuticals, 11/16/09

 See all of Financial Reports